- Stocks
- Pharma & Healthcare
- Anthem Biosciences
Anthem Biosciences share price
NSE: ANTHEMPharma & HealthcareBiotechnology
Anthem Biosciences at a glance
Anthem Biosciences (NSE: ANTHEM) closed at ₹802.40 on 22 Oct 2026, down 0.52% on the day. With a market capitalisation of ₹45,206 Cr, it ranks 209th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.
At its last close the stock traded at 76.6× trailing earnings, against a return on equity of 19.5% in FY26. Over the past year the share price has risen 3.0%. Its 52-week range is ₹579.15 (2 Feb 2026) to ₹977.55 (9 Sep 2026); the last close is 17.9% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹418 Cr (−22.6% year on year) and net profit ₹120 Cr (−11.7%), on a consolidated basis. Promoters held 71.42% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹45,206 CrRank 209 on NSE
- P/E (trailing)
- 76.6×
- Price to book
- 12.12×FY26
- EPS (TTM)
- ₹10.25to Q1 FY27
- ROE
- 19.5%FY26
- ROCE
- 27.6%FY26
- Debt to equity
- 0.02FY26
- Net profit margin
- 27.9%FY26
- Book value / share
- ₹54.16FY26
- 52-week high
- ₹977.559 Sep 2026
- 52-week low
- ₹579.152 Feb 2026
- 1-year return
- +3.0%
- RSI (14-day)
- 33
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.52% | −5.3% | −12.7% | +3.1% | +3.0% |
Anthem Biosciences quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹525 Cr | ₹498 Cr | ₹483 Cr | ₹540 Cr | ₹550 Cr | ₹423 Cr | ₹611 Cr | ₹418 Cr |
| Revenue YoY | — | — | — | +59.5% | +4.8% | −15.0% | +26.4% | −22.6% |
| Net profit | ₹162 Cr | ₹124 Cr | ₹83 Cr | ₹136 Cr | ₹173 Cr | ₹93 Cr | ₹190 Cr | ₹120 Cr |
| Net profit YoY | — | — | — | +64.8% | +7.1% | −25.3% | +129.7% | −11.7% |
| Net margin | 30.8% | 25.0% | 17.1% | 25.1% | 31.5% | 21.9% | 31.1% | 28.7% |
| EPS | ₹2.90 | ₹2.22 | ₹1.48 | ₹2.43 | ₹3.09 | ₹1.65 | ₹3.38 | ₹2.13 |
Anthem Biosciences financials
| Item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹1,057 Cr | ₹1,419 Cr | ₹1,845 Cr | — |
| Operating profit | ₹436 Cr | ₹477 Cr | ₹657 Cr | — |
| Net profit | ₹385 Cr | ₹367 Cr | ₹451 Cr | — |
| EPS (₹) | ₹7.00 | ₹6.00 | ₹8.00 | — |
| Cash from operations | ₹306 Cr | ₹140 Cr | ₹418 Cr | — |
| Total debt | ₹96 Cr | ₹112 Cr | ₹47 Cr | ₹28 Cr |
| Shareholders' equity | ₹1,741 Cr | ₹1,925 Cr | ₹2,410 Cr | ₹3,043 Cr |
Anthem Biosciences shareholding pattern
| Holder | 18 Jul 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|
| Promoters | 74.69% | 74.69% | 74.69% | 74.68% | 71.42% |
| Foreign institutions | 1.50% | 1.67% | 1.36% | 1.28% | 2.58% |
| Domestic institutions | 3.61% | 7.22% | 7.60% | 11.55% | 13.48% |
| Non-institutions | 20.20% | 16.42% | 16.35% | 12.50% | 12.53% |
Anthem Biosciences vs peers
The listed Pharma & Healthcare companies nearest to Anthem Biosciences by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| BIOCONBiocon | ₹332.85 | −0.19% | −5.1% | ₹54,244 Cr | 117.6 | — |
| ABBOTINDIAAbbott India | ₹25,445.00 | −1.57% | −15.3% | ₹54,069 Cr | 34.8 | — |
| IPCALABIPCA Laboratories | ₹1,932.90 | +0.62% | +48.4% | ₹49,038 Cr | 43 | — |
| GLANDGland Pharma | ₹2,910.60 | −0.66% | +52.0% | ₹48,013 Cr | 46.7 | — |
| ANTHEMAnthem Biosciences | ₹802.40 | −0.52% | +3.0% | ₹45,206 Cr | 76.6 | — |
| GLAXOGlaxoSmithKline Pharmaceuticals | ₹2,455.20 | +0.17% | −9.1% | ₹41,593 Cr | 40.1 | — |
| AJANTPHARMAjanta Pharma | ₹3,260.00 | 0.00% | +36.1% | ₹40,729 Cr | 38.6 | — |
Ask anything about Anthem Biosciences
Pivot answers on the live chart with evidence you can check, and tests strategies against ANTHEM's own history. Try: “Why has ANTHEM moved over the last three months?” · “Backtest a 50-day moving-average crossover on ANTHEM over five years” · “Compare ANTHEM with BIOCON on margins and valuation”
Frequently asked questions about Anthem Biosciences
What is the share price of Anthem Biosciences today?
Anthem Biosciences (NSE: ANTHEM) last closed at ₹802.40 on 22 Oct 2026. Its 52-week high is ₹977.55 and its 52-week low is ₹579.15.
What is the market cap of Anthem Biosciences?
Anthem Biosciences' market capitalisation is ₹45,206 Cr (₹45,206 Cr) at the 22 Oct 2026 close, ranking 209th among the NSE companies Pivot tracks.
What is the P/E ratio of Anthem Biosciences?
Anthem Biosciences trades at a trailing P/E of 76.6. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 43.
What is the ROE and ROCE of Anthem Biosciences?
Return on equity was 19.5% in FY26 and return on capital employed was 27.6% in FY26 (consolidated figures).
Is Anthem Biosciences a debt-free company?
Anthem Biosciences is close to debt-free: its debt-to-equity ratio was 0.02 in FY26.
What were Anthem Biosciences' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Anthem Biosciences reported revenue of ₹418 Cr, −22.6% year on year, and net profit of ₹120 Cr, −11.7% year on year.
How has Anthem Biosciences stock performed over the last year?
Anthem Biosciences' share price has risen 3.0% over the past year, +3.1% over three months and −12.7% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Anthem Biosciences?
As of 30 Jun 2026: promoters 71.42%, foreign institutions 2.58%, domestic institutions 13.48%, non-institutions 12.53%.
Who are Anthem Biosciences' competitors?
The listed Pharma & Healthcare companies closest to Anthem Biosciences by market cap are Biocon, Abbott India, IPCA Laboratories, Gland Pharma, GlaxoSmithKline Pharmaceuticals and Ajanta Pharma.
Is Anthem Biosciences a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Anthem Biosciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ANTHEM against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text